diabetic macular edema (dme) is a leading cause of vision loss in the working-age population worldwide. numerous early studies suggest an important role for intravitreal anti-vegf agents such as bevacizumab in the management of dme. we reviewed manuscripts that had investigated pharmacokinetic, efficacy, safety, dose and frequency of intravitreal bevacizumab (ivb) injections as well as effect o...

PURPOSE To evaluate the efficacy of vitrectomy combined with intravitreal injection of triamcinolone acetonide (IVTA) and macular laser photocoagulation for the treatment of nontractional diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) therapy. METHODS Twenty-eight eyes from 28 subjects who were diagnosed with nontractional DME refractory to three or ...

Purpose To describe the clinical response of refractory macular edema associated with Coats' disease following treatment with aflibercept and laser photocoagulation. Methods Case report. Results A 17-year-old female presented with decreased vision of the left eye. Ophthalmic exam demonstrated intraretinal hemorrhages and exudation with associated edema centrally. Angiographic evaluation rev...

PURPOSE To evaluate the efficacy of macular grid photocoagulation in preserving or improving central visual acuity in eyes with macular edema due to central vein occlusion (CVO) and best-corrected visual acuity of 20/50 or poorer. METHODS Patients with angiographically documented macular edema due to CVO were entered into a multicenter randomized controlled clinical trial supported by the Nat...

Macular oedema is a leading cause of vision loss in patients with radiation retinopathy. In an effort to find an effective treatment for this vision threatening complication, 12 eyes (eight patients) were treated with photocoagulation for clinically significant radiation macular oedema (CSRMO) defined as central macular thickening, exudates threatening the macular centre, or one disc area of th...

Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Thirty years ago, the Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that focal/grid laser photocoagulation reduces moderate vision loss from DME by 50% or more; thus, macular photocoagulation became the gold standard treatment for DME. However, with the development of anti-VEGF drugs (be...

purpose : to evaluate the effect of intraviteral bevacizumab (ivb) in diabetic macular edema (dme), using multifocal electroretinography (mferg) methods : sixty-four eyes of 32 patients with bilateral symmetric clinically significant macular edema (csme) were included in the study. after taking a baseline mferg, macular photocoagulation (mpc) was done in all eyes. after 7 days, 1.25 mg of bevac...

PURPOSE The aim of the present study was to investigate the effect of subthreshold diode laser micropulse (SDM) in comparison with conventional laser photocoagulation in the treatment of the diabetic macular edema (DME). METHODS Sixty-eight eyes from 68 patients with clinically significant DME were divided randomly into two equal groups. In the first group, SDM photocoagulation was employed, ...

PURPOSE Leber's miliary aneurysm is a variant of Coats' disease and similar to type 1 idiopathic macular telangiectasia. A recent report showed that an intravitreal injection of bevacizumab (IVB) was effective in an adult patient with type 1 idiopathic macular telangiectasia. We describe our experience with an adult patient with a macular edema caused by Leber's miliary aneurysm, which had not ...